<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134328</url>
  </required_header>
  <id_info>
    <org_study_id>10-100-0005</org_study_id>
    <nct_id>NCT01134328</nct_id>
  </id_info>
  <brief_title>Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aciex Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aciex Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its
      components in the prevention of the signs and symptoms of allergic conjunctivitis in
      Enviro-CAC™ Model.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of Episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Redness at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Redness at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Redness at 8 Hours Post-Dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Swelling at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Swelling Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Swelling at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ear or Palate Pruritus at 8 Hours Post-dose at Visit 4A</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Study Medication at Visit 2B</measure>
    <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
    <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Study Medication at Visit 3</measure>
    <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
    <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>AC-150 Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-150A 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AC-150B 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-150 Combo</intervention_name>
    <description>1 drop in each eye for up to 14 days</description>
    <arm_group_label>AC-150 Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-150A 0.1%</intervention_name>
    <description>1 drop in each eye once per day for up to 14 days</description>
    <arm_group_label>AC-150A 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC-150B 0.005%</intervention_name>
    <description>1 drop in each eye once per day for up to 14 days</description>
    <arm_group_label>AC-150B 0.005%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>1 drop in each eye once per day for up to 14 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive bilateral conjunctival allergen challenge(CAC) reaction

        Exclusion Criteria:

          -  Known contraindications or sensitivities to the study medication or its components.

          -  Any ocular condition that, in the opinion of the investigator, could affect the
             subjects safety or trial parameters.

          -  Use of disallowed medications during the period indicated prior to study enrollment or
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas P Marsico, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>East West Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ora, Inc</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>June 22, 2017</results_first_submitted>
  <results_first_submitted_qc>September 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2017</results_first_posted>
  <disposition_first_submitted>February 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 29, 2012</disposition_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from two sites in the US.</recruitment_details>
      <pre_assignment_details>There were 83 subjects enrolled, 12 subjects discontinued, and 71 subjects completed the study. Participant flow and baseline characteristics are presented for the 83 subjects that met all inclusion criteria and none of the exclusion criteria and were randomized to receive AC-150 Combo, AC-150A 0.1%, AC-150B 0.005% or Vehicle</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AC-150 Combo</title>
          <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
        </group>
        <group group_id="P2">
          <title>AC-150A 0.1%</title>
          <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="P3">
          <title>AC-150B 0.005%</title>
          <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="P4">
          <title>Vehicle</title>
          <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AC-150 Combo</title>
          <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
        </group>
        <group group_id="B2">
          <title>AC-150A 0.1%</title>
          <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="B3">
          <title>AC-150B 0.005%</title>
          <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="B4">
          <title>Vehicle</title>
          <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="12.56"/>
                    <measurement group_id="B2" value="35.1" spread="14.32"/>
                    <measurement group_id="B3" value="40.2" spread="12.23"/>
                    <measurement group_id="B4" value="38.3" spread="16.16"/>
                    <measurement group_id="B5" value="37.8" spread="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.974"/>
                    <measurement group_id="O2" value="0.99" spread="0.752"/>
                    <measurement group_id="O3" value="2.11" spread="1.173"/>
                    <measurement group_id="O4" value="2.90" spread="0.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.076"/>
                    <measurement group_id="O2" value="1.33" spread="0.590"/>
                    <measurement group_id="O3" value="2.25" spread="1.057"/>
                    <measurement group_id="O4" value="3.11" spread="0.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.033"/>
                    <measurement group_id="O2" value="1.59" spread="0.894"/>
                    <measurement group_id="O3" value="2.03" spread="1.131"/>
                    <measurement group_id="O4" value="2.97" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.112"/>
                    <measurement group_id="O2" value="1.92" spread="1.131"/>
                    <measurement group_id="O3" value="1.88" spread="1.082"/>
                    <measurement group_id="O4" value="3.04" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="1.160"/>
                    <measurement group_id="O2" value="2.24" spread="0.991"/>
                    <measurement group_id="O3" value="2.21" spread="1.132"/>
                    <measurement group_id="O4" value="3.18" spread="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="1.067"/>
                    <measurement group_id="O2" value="2.12" spread="1.156"/>
                    <measurement group_id="O3" value="2.11" spread="1.231"/>
                    <measurement group_id="O4" value="3.18" spread="0.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.007"/>
                    <measurement group_id="O2" value="1.53" spread="0.916"/>
                    <measurement group_id="O3" value="2.01" spread="0.872"/>
                    <measurement group_id="O4" value="2.99" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.022"/>
                    <measurement group_id="O2" value="1.83" spread="0.954"/>
                    <measurement group_id="O3" value="2.17" spread="0.899"/>
                    <measurement group_id="O4" value="2.90" spread="0.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.071"/>
                    <measurement group_id="O2" value="1.86" spread="0.925"/>
                    <measurement group_id="O3" value="2.03" spread="0.935"/>
                    <measurement group_id="O4" value="2.79" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.677"/>
                    <measurement group_id="O2" value="1.97" spread="0.812"/>
                    <measurement group_id="O3" value="2.18" spread="0.835"/>
                    <measurement group_id="O4" value="2.49" spread="0.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.704"/>
                    <measurement group_id="O2" value="2.25" spread="0.997"/>
                    <measurement group_id="O3" value="2.44" spread="0.770"/>
                    <measurement group_id="O4" value="2.58" spread="0.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.745"/>
                    <measurement group_id="O2" value="2.37" spread="0.980"/>
                    <measurement group_id="O3" value="2.51" spread="0.838"/>
                    <measurement group_id="O4" value="2.58" spread="0.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.451"/>
                    <measurement group_id="O2" value="1.78" spread="0.478"/>
                    <measurement group_id="O3" value="1.83" spread="0.485"/>
                    <measurement group_id="O4" value="2.01" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.507"/>
                    <measurement group_id="O2" value="1.84" spread="0.410"/>
                    <measurement group_id="O3" value="1.97" spread="0.484"/>
                    <measurement group_id="O4" value="2.15" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.424"/>
                    <measurement group_id="O2" value="1.88" spread="0.567"/>
                    <measurement group_id="O3" value="1.81" spread="0.511"/>
                    <measurement group_id="O4" value="2.04" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT) Population with Last Observation Carried Forward (LOCF)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.610"/>
                    <measurement group_id="O2" value="1.66" spread="0.560"/>
                    <measurement group_id="O3" value="1.81" spread="0.442"/>
                    <measurement group_id="O4" value="1.96" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.626"/>
                    <measurement group_id="O2" value="1.70" spread="0.518"/>
                    <measurement group_id="O3" value="1.85" spread="0.557"/>
                    <measurement group_id="O4" value="2.14" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.617"/>
                    <measurement group_id="O2" value="1.70" spread="0.581"/>
                    <measurement group_id="O3" value="1.81" spread="0.546"/>
                    <measurement group_id="O4" value="2.14" spread="0.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.898"/>
                    <measurement group_id="O2" value="1.84" spread="0.852"/>
                    <measurement group_id="O3" value="2.35" spread="0.834"/>
                    <measurement group_id="O4" value="2.37" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.956"/>
                    <measurement group_id="O2" value="2.25" spread="0.940"/>
                    <measurement group_id="O3" value="2.47" spread="0.865"/>
                    <measurement group_id="O4" value="2.54" spread="0.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="1.100"/>
                    <measurement group_id="O2" value="2.29" spread="0.953"/>
                    <measurement group_id="O3" value="2.51" spread="0.946"/>
                    <measurement group_id="O4" value="2.56" spread="0.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.577"/>
                    <measurement group_id="O2" value="1.81" spread="0.616"/>
                    <measurement group_id="O3" value="1.71" spread="0.626"/>
                    <measurement group_id="O4" value="2.03" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.578"/>
                    <measurement group_id="O2" value="1.90" spread="0.600"/>
                    <measurement group_id="O3" value="1.84" spread="0.712"/>
                    <measurement group_id="O4" value="2.10" spread="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.629"/>
                    <measurement group_id="O2" value="1.91" spread="0.637"/>
                    <measurement group_id="O3" value="1.72" spread="0.667"/>
                    <measurement group_id="O4" value="2.04" spread="0.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.759"/>
                    <measurement group_id="O2" value="1.65" spread="0.673"/>
                    <measurement group_id="O3" value="1.68" spread="0.557"/>
                    <measurement group_id="O4" value="2.01" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.702"/>
                    <measurement group_id="O2" value="1.69" spread="0.693"/>
                    <measurement group_id="O3" value="1.74" spread="0.603"/>
                    <measurement group_id="O4" value="2.18" spread="0.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.713"/>
                    <measurement group_id="O2" value="1.63" spread="0.650"/>
                    <measurement group_id="O3" value="1.68" spread="0.717"/>
                    <measurement group_id="O4" value="2.10" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.749"/>
                    <measurement group_id="O2" value="2.03" spread="0.888"/>
                    <measurement group_id="O3" value="2.35" spread="0.755"/>
                    <measurement group_id="O4" value="2.50" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.642"/>
                    <measurement group_id="O2" value="2.40" spread="0.960"/>
                    <measurement group_id="O3" value="2.51" spread="0.763"/>
                    <measurement group_id="O4" value="2.71" spread="0.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.816"/>
                    <measurement group_id="O2" value="2.53" spread="0.951"/>
                    <measurement group_id="O3" value="2.56" spread="0.855"/>
                    <measurement group_id="O4" value="2.71" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of Episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of Episcleral redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.575"/>
                    <measurement group_id="O2" value="2.12" spread="0.638"/>
                    <measurement group_id="O3" value="2.15" spread="0.538"/>
                    <measurement group_id="O4" value="2.37" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.564"/>
                    <measurement group_id="O2" value="2.24" spread="0.583"/>
                    <measurement group_id="O3" value="2.21" spread="0.663"/>
                    <measurement group_id="O4" value="2.53" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.528"/>
                    <measurement group_id="O2" value="2.22" spread="0.522"/>
                    <measurement group_id="O3" value="2.16" spread="0.606"/>
                    <measurement group_id="O4" value="2.47" spread="0.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.672"/>
                    <measurement group_id="O2" value="1.88" spread="0.644"/>
                    <measurement group_id="O3" value="2.04" spread="0.453"/>
                    <measurement group_id="O4" value="2.34" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.712"/>
                    <measurement group_id="O2" value="2.04" spread="0.607"/>
                    <measurement group_id="O3" value="2.07" spread="0.598"/>
                    <measurement group_id="O4" value="2.41" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.674"/>
                    <measurement group_id="O2" value="1.94" spread="0.705"/>
                    <measurement group_id="O3" value="2.07" spread="0.630"/>
                    <measurement group_id="O4" value="2.40" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Redness at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Redness at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="2.252"/>
                    <measurement group_id="O2" value="5.96" spread="2.450"/>
                    <measurement group_id="O3" value="6.99" spread="2.230"/>
                    <measurement group_id="O4" value="7.37" spread="2.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" spread="2.225"/>
                    <measurement group_id="O2" value="7.03" spread="2.802"/>
                    <measurement group_id="O3" value="7.49" spread="2.312"/>
                    <measurement group_id="O4" value="7.87" spread="2.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="2.579"/>
                    <measurement group_id="O2" value="7.32" spread="2.778"/>
                    <measurement group_id="O3" value="7.60" spread="2.631"/>
                    <measurement group_id="O4" value="7.88" spread="2.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Redness at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Redness at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="1.451"/>
                    <measurement group_id="O2" value="5.75" spread="1.658"/>
                    <measurement group_id="O3" value="5.66" spread="1.591"/>
                    <measurement group_id="O4" value="6.40" spread="1.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="1.483"/>
                    <measurement group_id="O2" value="6.03" spread="1.489"/>
                    <measurement group_id="O3" value="5.88" spread="1.898"/>
                    <measurement group_id="O4" value="6.78" spread="1.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="1.402"/>
                    <measurement group_id="O2" value="6.10" spread="1.606"/>
                    <measurement group_id="O3" value="5.68" spread="1.736"/>
                    <measurement group_id="O4" value="6.54" spread="1.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Redness at 8 Hours Post-Dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Redness at 8 Hours Post-Dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Total redness was defined as the sum of the conjunctival, ciliary and episcleral redness scores, and was, thus, on a 0-12 scale, making the threshold for clinical significance a treatment difference of 3.0 units. Higher scores represent greater severity.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="1.955"/>
                    <measurement group_id="O2" value="5.25" spread="1.803"/>
                    <measurement group_id="O3" value="5.50" spread="1.389"/>
                    <measurement group_id="O4" value="6.29" spread="1.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="1.927"/>
                    <measurement group_id="O2" value="5.50" spread="1.730"/>
                    <measurement group_id="O3" value="5.63" spread="1.680"/>
                    <measurement group_id="O4" value="6.72" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="1.905"/>
                    <measurement group_id="O2" value="5.35" spread="1.831"/>
                    <measurement group_id="O3" value="5.54" spread="1.859"/>
                    <measurement group_id="O4" value="6.63" spread="1.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lid Swelling at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Lid Swelling at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.43"/>
                    <measurement group_id="O2" value="0.5" spread="0.50"/>
                    <measurement group_id="O3" value="1.2" spread="0.88"/>
                    <measurement group_id="O4" value="1.4" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.61"/>
                    <measurement group_id="O2" value="0.7" spread="0.75"/>
                    <measurement group_id="O3" value="1.1" spread="0.97"/>
                    <measurement group_id="O4" value="1.5" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.62"/>
                    <measurement group_id="O2" value="0.9" spread="0.75"/>
                    <measurement group_id="O3" value="1.1" spread="0.86"/>
                    <measurement group_id="O4" value="1.5" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lid Swelling Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Lid Swelling Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 16 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.51"/>
                    <measurement group_id="O2" value="1.2" spread="0.95"/>
                    <measurement group_id="O3" value="1.1" spread="0.86"/>
                    <measurement group_id="O4" value="1.5" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.59"/>
                    <measurement group_id="O2" value="1.3" spread="1.00"/>
                    <measurement group_id="O3" value="1.1" spread="0.86"/>
                    <measurement group_id="O4" value="1.6" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.59"/>
                    <measurement group_id="O2" value="1.3" spread="0.92"/>
                    <measurement group_id="O3" value="1.2" spread="0.95"/>
                    <measurement group_id="O4" value="1.7" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lid Swelling at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Lid Swelling at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 8 hours after drop instillation. Lid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of lid swelling score over both eyes was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.51"/>
                    <measurement group_id="O2" value="0.7" spread="0.58"/>
                    <measurement group_id="O3" value="1.1" spread="1.03"/>
                    <measurement group_id="O4" value="1.6" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.50"/>
                    <measurement group_id="O2" value="1.0" spread="0.76"/>
                    <measurement group_id="O3" value="1.1" spread="1.00"/>
                    <measurement group_id="O4" value="1.6" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.50"/>
                    <measurement group_id="O2" value="1.0" spread="0.88"/>
                    <measurement group_id="O3" value="1.0" spread="0.94"/>
                    <measurement group_id="O4" value="1.6" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.78"/>
                    <measurement group_id="O2" value="0.3" spread="0.59"/>
                    <measurement group_id="O3" value="0.5" spread="0.94"/>
                    <measurement group_id="O4" value="1.2" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.85"/>
                    <measurement group_id="O2" value="0.6" spread="0.93"/>
                    <measurement group_id="O3" value="0.7" spread="1.10"/>
                    <measurement group_id="O4" value="1.4" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.04"/>
                    <measurement group_id="O2" value="0.8" spread="0.90"/>
                    <measurement group_id="O3" value="1.0" spread="1.27"/>
                    <measurement group_id="O4" value="1.5" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.85"/>
                    <measurement group_id="O2" value="0.4" spread="0.62"/>
                    <measurement group_id="O3" value="0.4" spread="0.87"/>
                    <measurement group_id="O4" value="1.5" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.13"/>
                    <measurement group_id="O2" value="1.3" spread="0.99"/>
                    <measurement group_id="O3" value="0.6" spread="1.11"/>
                    <measurement group_id="O4" value="1.5" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.08"/>
                    <measurement group_id="O2" value="1.2" spread="1.03"/>
                    <measurement group_id="O3" value="0.9" spread="1.43"/>
                    <measurement group_id="O4" value="1.5" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ear or Palate Pruritus at 8 Hours Post-dose at Visit 4A</title>
        <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ear or Palate Pruritus at 8 Hours Post-dose at Visit 4A</title>
          <description>A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.</description>
          <population>Per protocol population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.69"/>
                    <measurement group_id="O2" value="0.7" spread="0.85"/>
                    <measurement group_id="O3" value="0.6" spread="1.06"/>
                    <measurement group_id="O4" value="1.2" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.78"/>
                    <measurement group_id="O2" value="1.1" spread="1.05"/>
                    <measurement group_id="O3" value="0.8" spread="1.24"/>
                    <measurement group_id="O4" value="1.2" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.86"/>
                    <measurement group_id="O2" value="1.2" spread="1.01"/>
                    <measurement group_id="O3" value="0.8" spread="1.20"/>
                    <measurement group_id="O4" value="1.3" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Study Medication at Visit 2B</title>
        <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
        <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
        <population>Intent to Treat (ITT). Number of analyzed subjects differ due to subject discontinuation during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Study Medication at Visit 2B</title>
          <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
          <population>Intent to Treat (ITT). Number of analyzed subjects differ due to subject discontinuation during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.94"/>
                    <measurement group_id="O2" value="2.2" spread="2.19"/>
                    <measurement group_id="O3" value="1.1" spread="1.54"/>
                    <measurement group_id="O4" value="2.0" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.59"/>
                    <measurement group_id="O2" value="2.0" spread="2.08"/>
                    <measurement group_id="O3" value="0.9" spread="1.45"/>
                    <measurement group_id="O4" value="1.7" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.41"/>
                    <measurement group_id="O2" value="1.4" spread="1.82"/>
                    <measurement group_id="O3" value="0.8" spread="1.25"/>
                    <measurement group_id="O4" value="1.6" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Study Medication at Visit 3</title>
        <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
        <time_frame>upon instillation, 1 minute and 2 minutes post instillation</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>AC-150 Combo</title>
            <description>AC-150 Combo: 1 drop in each eye for up to 14 days</description>
          </group>
          <group group_id="O2">
            <title>AC-150A 0.1%</title>
            <description>AC-150A 0.1%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O3">
            <title>AC-150B 0.005%</title>
            <description>AC-150B 0.005%: 1 drop in each eye once per day for up to 14 days</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Study Medication at Visit 3</title>
          <description>Subjects were asked to rate the comfort of the drop in each eye upon instillation, at 1 minute, and at 2 minutes after instillation of study medication. The assessment used a 10-point scale with 0 as very comfortable and 10 as very uncomfortable. Higher scores represent a worse outcome.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Upon instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.86"/>
                    <measurement group_id="O2" value="1.5" spread="2.12"/>
                    <measurement group_id="O3" value="0.9" spread="1.18"/>
                    <measurement group_id="O4" value="1.4" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 minute post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.31"/>
                    <measurement group_id="O2" value="1.4" spread="1.42"/>
                    <measurement group_id="O3" value="0.8" spread="1.06"/>
                    <measurement group_id="O4" value="1.0" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 minutes post-instillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.33"/>
                    <measurement group_id="O2" value="1.3" spread="1.25"/>
                    <measurement group_id="O3" value="0.7" spread="0.96"/>
                    <measurement group_id="O4" value="0.8" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through the completion of the study, approximately two months. All subjects who received study medication were evaluable for the safety analysis.</time_frame>
      <desc>Throughout the visit, staff collected all Adverse Events reported, elicited or observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>AC-150 Combo</title>
          <description>AC-150: 1 drop in each eye for up to 14 days</description>
        </group>
        <group group_id="E2">
          <title>AC-150A 0.1%</title>
          <description>AC-150A: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="E3">
          <title>AC-150B 0.005%</title>
          <description>AC-150B: 1 drop in each eye once per day for up to 14 days</description>
        </group>
        <group group_id="E4">
          <title>Vehicle</title>
          <description>Vehicle: 1 drop in each eye once per day for up to 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael V.W. Bergamini, PhD - Chief Scientific Officer/Executive Vice President</name_or_title>
      <organization>Nicox Ophthalmics Inc.</organization>
      <phone>817-529-9315</phone>
      <email>bergamini@nicox.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

